Young people with IBD five times more likely to develop serious infections, new study reveals

Young people with IBD five times more likely to develop serious infections, new study reveals

(Vienna, December 5, 2019) Young patients with inflammatory bowel disease (IBD) are five times more likely than the general population to develop viral infections that can lead to hospitalisation or permanent organ damage, a new study published in the UEG Journal has found. 

In the first study of its kind, researchers analysed almost 2,700 IBD patients in a Paris referral centre to understand the respective roles of IBD activity and drugs in promoting systemic serious viral infection (SVI). The study identified clinically active IBD and thiopurines (a class of immunomodulators used to treat an estimated 60% of IBD patients) as the main drivers of infection. Despite the highest risk of infection being seen in young patients between the ages of 18 and 35, a three-fold increased incidence of severe viral infections was observed in IBD patients of all ages.  The study also uncovered a concerning link between thiopurine use and a number of harmful infections. Whilst IBD patients receiving no treatment were at a similar risk level to the general population, patients treated with immunomodulators were found to be six times more likely to develop an SVI. The most common SVIs developed by IBD patients were identified as Epstein-Barr virus (EBV), which is associated with a range of diseases such as glandular fever and Hodgkin’s Lymphoma, and cytomegalovirus (CMV), an infection which can pose a risk to unborn babies.  A correlation was also found between thiopurine use and EBV-induced hemophagocytic lymphohistiocytosis (HLH), an aggressive disease associated with high mortality rates. With a third of patients estimated to be stopping thiopurine use due to adverse side effects, these new findings underline the need to find novel therapeutic approaches to tackle IBD.  Lead researcher Professor Laurent Beaugerie, from the Department of Gastroenterology at Saint-Antoine Hospital, commented, “Clinicians need to be aware of the substantially increased risk of SVI in patients with IBD, which had previously remained unclear. Young IBD patients are the most vulnerable to the development of SVIs, as they are less likely to have been exposed to viruses such as EBV or CMV before. They will therefore mount a less effective immune response. Their risk is further elevated by the inhibiting effect of the immunosuppressive drugs they are treated with.”  The number of individual IBD cases, which encompasses both Crohn’s disease and ulcerative colitis, has shown a marked increase since 1990, rising from 3.6 million cases globally to over 6.8 million in 2017. Commenting on the increasingly heavy burden of IBD, Professor Beaugerie added, “The relation between IBD drugs and SVIs is especially concerning, as presently, hospitalisation due to the serious complications that accompany the disease is the main cost associated with the management of IBD. The growing prevalence of IBD across the globe will only add further to the pressure placed on healthcare structures.”  New treatment pathways such as nutritional therapies in Crohn’s disease and faecal microbiota transplantations (FMT), which are not evidenced to be associated with an increased risk of SVI, could potentially alleviate the strain placed on healthcare systems. Therapies such as these could transform the course of treatment and confer significant benefits to patients.  The study, which has cast new light on the strong association between IBD drugs and SVI, emphasises the need for further research and funding into the area to improve patient outcomes. An investigation into promising new treatments should become the next course of action if the risk of SVI in IBD patients is to be brought closer that of the general population.  Notes to Editors  For further information, or to arrange an interview with Professor Laurent Beaugerie, please contact Hannah Murray on +44 (0)1444 811099 or media@ueg.eu  We kindly ask that a reference to UEG is included when communicating any information within this press release.  About Professor Laurent Beaugerie Laurent Beaugerie is Professor of Gastroenterology at Saint-Antoine hospital, Pierre et Marie Curie Paris-6 University, Paris, France, past-president of the national French Society of Gastroenterology and member of the AGA.  About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European medical specialist and national societies focusing on digestive health.  Our member societies represent more than 30,000 specialists from every field of gastroenterology. Together, we provide services for all healthcare professionals and researchers, in the broad area of digestive health. The role of UEG is to take concerted efforts to learn more about digestive disease by prevention, research, diagnosis, cure and raising awareness of their importance. To advance the standards of gastroenterological care and knowledge across the world and to reduce the burden of digestive diseases, UEG offers numerous activities and initiatives, including:
  • UEG Week, the biggest congress of its kind in Europe, and one of the two largest in the world
  • UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
  • Activity Grants, promoting and funding educational projects in the field of digestive health to advance and harmonise the training and continuing education of professionals
  • UEG Journal, covering translational and clinical studies from all areas of gastroenterology
  • Public Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
  • Quality of Care, European-based and English clinical practice guidelines, clinical standards, consensus, position papers and standard protocols in the field of digestive health, are available in the repository.
Find out more about UEG’s work by visiting www.ueg.eu or contact:                Hannah Murray on +44 (0)1444 811099 or media@ueg.eu  Follow UEG on Twitter  References 
  1. Beaugerie L et al. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines, United European Gastroenterology Journal, 2019;0(0):1-11.
  2. Warner B, Johnston E, Arenas-Hernandez M, et al. A practical guide to thiopurine prescribing and monitoring in IBD, Frontline Gastroenterology, 2016;0:1-6.
  3. Fox CP et al. Epstein-Barr Virus- Associated Hemophagocytic Lymphohistiocytosis in Adults Characterized by High Viral Genome Load within Circulating Natural Killer Cells, Clinical Infectious Diseases, 2010;51(1):66-69.
  4. GBD 2017 Inflammatory Bowel Disease Collaborators, The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017, The Lancet Gastroenterology & Hepatology, 2017.

UEG Week: Colorectal and pancreatic cancer rates up 10% in last 30 years, reveals major global study

UEG Week: Colorectal and pancreatic cancer rates up 10% in last 30 years, reveals major global study

(Barcelona, October 22, 2019) The results of a major study across 195 countries, presented today at UEG Week Barcelona 2019, indicate that global death rates for pancreatic cancer and incidence rates for colorectal cancer both increased by 10% between 1990 and 2017. 

The Global Burden of Disease study, is the first to provide comprehensive worldwide estimates of the burden, epidemiological features and risk factors of a number of digestive diseases. Funded by the Bill & Melinda Gates Foundation, the study has also been published today in The Lancet Gastroenterology & Hepatology.  Key findings also include:
  • The number of pancreatic cancer cases increased by 130% over the 27-year study period, from 195,000 in 1990 to 448,000 in 2017
  • Gastric (stomach) cancer dropped from the second leading cause of cancer death worldwide to the third, behind both lung and colorectal cancer
  • The number of cases of inflammatory bowel disease (IBD) increased 84%, from 3.7 million in 1990 to 6.8 million in 2017 
Commenting on the study, Professor Herbert Tilg, Chair of the UEG Scientific Committee, stated, “This analysis provides the most comprehensive picture of the global burden of digestive disease to date. Examining these cross-populational trends offers vital information on the changing burden of disease and aids the correct allocation of resources to improve patient outcomes.”  Pancreatic cancer patients more likely to survive in 1990 than today As well as an increase in pancreatic cancer cases, the number of deaths also rose from 196,000 in 1990 to 448,000 in 2017. Whilst some of this increase can be explained by the rising population and longevity, even after accounting for population changes, age-standardised incidence and death rates for pancreatic cancer increased by 12% and 10% respectively. Of note, the highest incidence and death rates were found in higher-income countries.  Experts believe the increase is related to a rise in the prevalence of obesity and diabetes, as reflected by the risk factors of high BMI and higher blood glucose levels which are two of the leading risk factors for pancreatic cancer.  Professor Reza Malekzadeh, lead author of the study, commented, “Pancreatic cancer is one of the world’s deadliest cancers, with an overall five-year survival rate of just 5% in high, middle and low-income countries. Major risk factors for the disease, such as smoking, diabetes and obesity, are largely modifiable and present a huge opportunity for prevention.”  Screening key in reducing the burden of colorectal cancer From 1990 to 2017, age-standardised incidence rates for colorectal cancer increased 9.5% globally but, by contrast, age-standardised death rates decreased by 13.5%. The researchers believe that this is due to the introduction of colorectal cancer screening programmes, leading to earlier detection and an increased chance of survival. Similarly, in countries where screening programmes were established two or three decades ago, reductions in death rates were observed, supporting the benefits attributable to screening interventions.  The study also indicated that the risk factors for colorectal cancer are different in males and females, and should therefore be considered in national policy and prevention programmes. Alcohol use, smoking and diets low in calcium, milk and fibre had a considerable burden on males. For females, dietary risks, but not alcohol use or smoking, were found to be the most attributable risks.  Experts recommend local strategies to tackle gastric cancer  Age-standardised incidence and death rates for gastric cancer decreased steadily between 1990 and 2017. However, this decline has not necessarily led to a lower burden on the health system in high-risk countries and experts believe that specific local strategies should be tailored to each country’s risk factor profile.  “This research shows how gastric cancer presents vast geographical variations, and understanding these differential trends is essential for formulating effective preventative strategies”, commented Professor Reza Malekzadeh. “Beyond the current decline in incidence and death rates, a decrease in the absolute number of cases and deaths will be possible if the burden in east Asia, where currently almost half of the cases and deaths occur, is further reduced.”  - ENDS - Notes to Editors  For further information, or to arrange an expert interview with, please contact Luke Paskins on +44 (0)1444 811099 or +44 (0) 7732 499170 or media@ueg.eu  We kindly ask that a reference to UEG Week 2019 is included when communicating any information within this press release. Links to Full Papers: Colorectal Cancer Pancreatic Cancer Stomach Cancer IBD About Professor Herbert Tilg Professor Herbert Tilg is the Chair of the UEG Scientific Committee and a Professor at the Medical University of Innsbruck, Austria.  About Professor Reza Malekzadeh Professor Reza Malekzadeh is a Professor of Medicine and Director of the Digestive Disease Institute at Tehran University of Medical Sciences, Tehran, Iran. About UEG Week UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning. About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European medical specialist and national societies focusing on digestive health. Our member societies represent more than 30,000 specialists from every field of gastroenterology. Together, we provide services for all healthcare professionals and researchers, in the broad area of digestive health. The role of UEG is to take concerted efforts to learn more about digestive disease by prevention, research, diagnosis, cure and raising awareness of their importance.  To advance the standards of gastroenterological care and knowledge across the world and to reduce the burden of digestive diseases, UEG offers numerous activities and initiatives, including:
  • UEG Week, the biggest congress of its kind in Europe, and one of the two largest in the world
  • UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
  • Activity Grants, promoting and funding educational projects in the field of digestive health to advance and harmonise the training and continuing education of professionals
  • UEG Journal, covering translational and clinical studies from all areas of gastroenterology
  • Public Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
  • Quality of Care, European-based and English clinical practice guidelines, clinical standards, consensus, position papers and standard protocols in the field of digestive health, are available in the repository.
Find out more about UEG’s work by visiting www.ueg.eu or contact:     Luke Paskins on +44 (0)1444 811099 or media@ueg.eu  Follow UEG on Twitter References
  1. Malekzadeh, R. et al (2019). The global, regional and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Presented at UEG Week Barcelona 2019, October 22, 2019. Published in The Lancet Gastroenterology and Hepatology.  
  2. Malekzadeh, R. et al (2019). The global, regional and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Presented at UEG Week Barcelona 2019, October 22, 2019. Published in The Lancet Gastroenterology and Hepatology.  
  3. Malekzadeh, R. et al (2019). The global, regional and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Presented at UEG Week Barcelona 2019, October 22, 2019. Published in The Lancet Gastroenterology and Hepatology.  
  4. Malekzadeh, R. et al (2019). The global, regional and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Presented at UEG Week Barcelona 2019, October 22, 2019. Published in The Lancet Gastroenterology and Hepatology.  

UEG Week: IBD prevalence three times higher than previous estimates and expected to rise further, new study reveals

UEG Week: IBD prevalence three times higher than previous estimates and expected to rise further, new study reveals

(Barcelona, October 21, 2019) The number of people suffering from inflammatory bowel diseases (IBD) is three times higher than previous estimates, with sufferers also at a higher risk of developing colorectal cancer (CRC), according to new research presented today at UEG Week Barcelona 2019. 

Researchers from Sandwell and West Birmingham Hospitals NHS trust and the University of Birmingham examined IBD cases from the beginning of the century to attain accurate data on ulcerative colitis (UC) and Crohn’s Disease (CD) prevalence in the UK. Previously, only limited or old data existed, but by utilising data from the Health Improvement Network (THIN), a nationally representative UK primary care database, this new evidence demonstrates that IBD prevalence is three times higher than previously reported, with UC and CD prevalence increasing by 55% and 83% respectively, between 2000 and 2017. The study also showed that IBD prevalence is predicted to rise by almost a quarter from 2017 to 2025.   Affecting over 3 million people across Europe, inflammatory bowel diseases are a group of disorders involving chronic inflammation of the gut. The severity of the symptoms and the long-lasting nature of the diseases can have an extremely debilitating impact on the lives of sufferers. For example, higher rates of depression and reduced workforce participation in patients with UC and CD has been reported in previous studies, with an estimated 44% of IBD sufferers claiming they had lost or quit their job because of IBD. Researcher, Dominic King, from the University of Birmingham, who is presenting the findings for the first time at UEG Week, comments “Our study suggests that IBD prevalence is likely to rise substantially over the next decade. As there is currently no known cure for IBD, patients will often need complex and costly treatments throughout their lives. This predicted rise in prevalence may place an even greater strain on already overburdened healthcare systems.”  “The burden of IBD is compounded further by an association with colorectal cancer”, comments Dr King. “Our study found that patients suffering from Crohn’s disease had a 23% increased risk of developing CRC compared to matched controls, whilst ulcerative colitis patients had a significantly elevated risk of 43%. The rise in prevalence of IBD could therefore potentially lead to an associated rise in CRC cases.”  Accurate evidence on the IBD burden is essential for service planning to ensure patients receive an excellent standard of care across Europe. “The results of the study are alarming, particularly if we consider the fact that Crohn’s disease and ulcerative colitis are lifelong diseases that can begin at a young age and have a huge impact on a patient’s quality of life”, commented Salvo Leone, President of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA). “The cost to society, either through direct medical costs or indirect costs such as lost days at work, lost educational opportunities, or caring for an affected family member, are enormous. We need to put all our efforts into developing effective treatment and disease management strategies that allow patients and their families to lead happier and healthier lives.” Notes to Editors  For further information, or to arrange an interview with Dr Dominic King, please contact Luke Paskins on +44 (0)1444 811099 or +44 (0) 7732 499170 or by email media@ueg.eu  We kindly ask that a reference to UEG Week 2019 is included when communicating any information within this press release.   About Dr Dominic King Dr Dominic King is a gastroenterology trainee based in the West Midlands, UK. He attained his medical degree at the University of Birmingham. He is currently undertaking a doctoral research programme, investigating the inflammatory bowel diseases using routinely gathered data from both primary and secondary care.  About EFCCA The European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) is an umbrella organisation representing 39 national Crohn’s and Ulcerative Colitis (collectively known as Inflammatory Bowel Disease or IBD) patient associations.  We are an organization of people united in our commitment to improve the life of the over 10 million people living with IBD worldwide (3.4 million in Europe alone) and to give them a louder voice and more visibility.  About UEG Week UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning.  About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European medical specialist and national societies focusing on digestive health.  Our member societies represent more than 30,000 specialists from every field of gastroenterology. Together, we provide services for all healthcare professionals and researchers, in the broad area of digestive health. The role of UEG is to take concerted efforts to learn more about digestive disease by prevention, research, diagnosis, cure and raising awareness of their importance.  To advance the standards of gastroenterological care and knowledge across the world and to reduce the burden of digestive diseases, UEG offers numerous activities and initiatives, including:
  • UEG Week, the biggest congress of its kind in Europe, and one of the two largest in the world
  • UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
  • Activity Grants, promoting and funding educational projects in the field of digestive health to advance and harmonise the training and continuing education of professionals
  • UEG Journal, covering translational and clinical studies from all areas of gastroenterology
  • Public Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
  • Quality of Care, European-based and English clinical practice guidelines, clinical standards, consensus, position papers and standard protocols in the field of digestive health, are available in the repository. 
Find out more about UEG’s work by visiting www.ueg.eu or contact:     Luke Paskins on +44 (0)1444 811099 or media@ueg.eu  Follow UEG on Twitter  References
  1. King. D et al. 2019. Incidence and Prevalence of Inflammatory Bowel Disease in the UK between 2000 and 2016 and Associated Mortality and subsequent risk of Colorectal Cancer. Presented at UEG Week October 21, 2019.
  2. The European Federation of Crohn’s & Ulcerative Colitis Associations (EFCCA), Basic Information, Brussels. (ONLINE): Available at: http://www.efcca.org/en/basic-information
  3. Burisch. J, Jess. T, Martinato. M, Lakatos. P, on behalf of ECCO-EpiCom (2013). The burden of inflammatory bowel disease in Europe. Journal of Crohn’s and Colitis, Volume 4, Issue 4, pp. 322-337. 

Millions of Europeans at risk of chronic digestive diseases, new report reveals

Millions of Europeans at risk of chronic digestive diseases, new report reveals

(Vienna, May 21, 2019) Poor nutritional choices, including a high intake of ultra-processed foods and trans-fats, are putting millions of Europeans at an increased risk of a range of chronic digestive diseases, including digestive cancers, wheat related disorders and functional GI disorders, as well as obesity, a new report shows. 

‘Nutrition and Chronic Digestive Diseases’, launched today by United European Gastroenterology (UEG) and supported by twelve medical associations, patient organisations and NGOs, canvasses the opinion of a number of leading experts in the fields of nutrition, digestive cancers, liver diseases, functional gastrointestinal disorders and paediatrics.  The Ultra-processed Food Endemic:
The report outlines how ultra-processed foods, which are often high in fat, added sugar and salt, now frequently contribute to up to half of modern European energy intake and, in some countries, over 75% of mean energy intake.  Consumption of ultra-processed foods has dramatically increased in recent decades, with common examples including soft drinks, confectionary, crisps and frozen ready meals. Studies have shown that the consumption of ultra-processed foods is associated with an increased risk of cancer and suggest that the rapidly increasing consumption of these food types may be driving the growing cancer burden. A 10% increase in the proportion of ultra-processed foods in the diet, for example, is associated with a 12% increased overall cancer risk.  In addition to a raised risk of chronic diseases, high consumption of these foods also increases the prevalence of obesity. Alarmingly, over half (52%) of the EU’s population aged 18 and over is now overweight or obese and 1 in 3 of Europe’s school children are estimated to be overweight. “Obesity, often driven by poor nutritional choices, increases the risk of a range of serious digestive health conditions and causes a significant healthcare burden, high societal costs, misery for patients and, ultimately, shortens lives”, explains Professor Markus Peck, Department of Internal Medicine and Gastroenterology at Klinikum Klagenfurt am Wörthersee, Austria. “Healthy balanced diets and lifestyles can help prevent chronic digestive diseases but the difficulty we face is ensuring our citizens make the right choices in following these lifestyles.” An Action Plan for Europe:
The report makes a number of recommendations in order to reduce the risk and impact of chronic digestive diseases, including: 
  • Less than 10% (<50 grams), but ideally 5%, of total daily energy intake of sugar
  • Less than 10% of total daily energy intake of saturated fats
  • Less than 1% of total daily energy intake of trans-fats
  • Less than 5g of salt per day
“We need the European Commission and national governments to act now on initiatives to change the way in which we buy and consume food”, states Professor Peck. “Our aim should be to achieve a European-wide transformation to healthy diets by 2050. This would require the consumption of fruits, vegetables, nuts and legumes to double, and consumption of foods such as red meat and sugar to be reduced by more than 50% over the next 30 years.”  “If we are to fight the burgeoning prevalence of overweight, obese and unhealthy people in Europe, and the healthcare burden and loss of life that it brings, then we must act now”, concludes Professor Peck.  

% Adult Obesity Rates in Europe (*self-report data)

Country

Male Obesity %

Female Obesity %

Malta

36.9

31.3

Romania

29.4

34.1

Greece

27.9

25.6

England

27.4

30

Cyprus

27

28.8

Scotland

27

30

Ireland (Northern)

26

27

Ireland (Republic)

25.8

21.3

Portugal

25.5

32

Italy

24.5

24.9

Poland

24.2

23.4

Luxembourg

24.1

21

Czech Republic

23.9

22.3

Germany

23.3

23.9

Spain

22.8

20.5

Hungary*

22

20.4

Wales*

22

23

Slovenia *

21

17.4

Croatia

20.7

16.8

Finland

20.4

19

Estonia*

19.1

21.5

Latvia*

18.8

23.3

Slovakia

18.1

15.9

France

16.8

17.4

Sweden

15.5

14.4

Denmark *

14.1

15.6

Belgium

13.9

14.2

Austria

13.4

10.7

Bulgaria

13.4

19.2

Lithuania

11.3

15.2

Netherlands

10.4

10.1
  

% Childhood Overweight Rates in Europe (*self-report data)

Country

Male Overweight %

Female Overweight %

Malta

43.2

38.7

Croatia

38.7

31

Italy

37.2

34.7

Spain

32.3

29.5

Cyprus

31.5

25.6

Greece

31

29.1

Portugal

30.9

32

Bulgaria

30.4

28.3

Denmark*

29.3

21.1

England

28.6

29

Ireland (Northern)

28

25

Austria

28

25.9

Slovenia*

27.4

22.7

Wales*

27.1

27

Latvia*

25

21

Romania

24.6

22.6

Germany

24.2

23.8

Scotland

24

29

Finland

23.8

20.1

Czech Republic

23

20

Luxembourg

23

22

Slovakia

22.6

20.7

Sweden

22.6

21.2

Lithuania

21.4

19.9

Hungary*

21.4

23.7

Poland

20.8

14.4

Belgium

16.9

13.5

Netherlands

16.8

15.4

Ireland (Republic)

16

19

France

14.4

18.7

Estonia*

13.6

14.9
Notes to Editors For further information, or to arrange an expert interview, please contact Luke Paskins on +44 (0)1444 811099 or media@ueg.eu About the Report Access ‘Nutrition and Chronic Digestive Diseases: An Action Plan for Europe’ The report was produced by UEG, with support and endorsement from:
  • The Association of European Coeliac Societies (AOECS)
  • Digestive Cancers Europe (DiCE)
  • The European Association for Gastroenterology, Endoscopy and Nutrition (EAGEN)
  • The European Association for the Study of the Liver (EASL)
  • The European Cancer Organisation (ECCO)
  • The European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA)
  • The European Helicobacter and Microbiota Study Group (EHMSG)
  • The European Society of Digestive Oncology (ESDO)
  • The European Society of Neurogastroenterology and Motility (ESNM)
  • The European Society for Clinical Nutrition and Metabolism (ESPEN)
  • The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
  • The World Gastroenterology Organisation (WGO)
About Professor Markus Peck
Professor Markus Peck is the Chairman at the Department of Internal Medicine and Gastroenterology (IMuG) at Klinikum Klagenfurt am Wörthersee in Klagenfurt, Austria. He is the Chair of the UEG Public Affairs Committee. About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European medical specialist and national societies focusing on digestive health. Together, its member societies represent over 30,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. To advance the standards of gastroenterological care and knowledge across the world and to reduce the burden of digestive diseases, UEG offers numerous activities and initiatives, including:
  • UEG Week, the biggest congress of its kind in Europe, and one of the two largest in the world
  • UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
  • Activity Grants, promoting and funding educational projects in the field of digestive health to advance and harmonise the training and continuing education of professionals
  • UEG Journal, covering translational and clinical studies from all areas of gastroenterology
  • Public Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
  • Quality of Care, European-based and English clinical practice guidelines, clinical standards, consensus, position papers and standard protocols in the field of digestive health, are available in the repository. 
Find out more about UEG’s work by visiting www.ueg.eu or contact:               Luke Paskins on +44 (0)1444 811099 or media@ueg.eu

UEG Week: Cannabis significantly improves the symptoms of Crohn’s disease despite having no effect on gut inflammation

UEG Week: Cannabis significantly improves the symptoms of Crohn’s disease

(Vienna, October 22, 2018) In the first study of its kind, cannabis oil has been shown to significantly improve the symptoms of Crohn’s disease and the quality of life of sufferers but, contrary to previous medical thinking, has no effect on gut inflammation.

In a randomised, placebo-controlled study, researchers from Israel have shown that cannabis can produce clinical remission in up to 65% of individuals after 8 weeks of treatment, but that this improvement does not appear to result from a dampening down of the underlying inflammatory process. Speaking at UEG Week 2018 in Vienna, lead researcher, Dr Timna Naftali explained, “Cannabis has been used for centuries to treat a wide range of medical conditions, and studies have shown that many people with Crohn’s disease use cannabis regularly to relieve their symptoms.It has always been thought that this improvement was related to a reduction in inflammation in the gut and the aim of this study was to  investigate this.”  The Israeli team recruited 46 people with moderately severe Crohn’s disease, and randomized them to receive 8 weeks of treatment with either cannabis oil containing 15% cannabidiol and 4% tetrahydrocannabinol or placebo. Symptom severity and quality of life were measured before, during, and after treatment using validated research instruments. Inflammation in the gut was assessed endoscopically and by measuring inflammatory markers in blood and stool samples.  After 8 weeks of treatment, the group receiving the cannabis oil had a significant reduction in their Crohn’s disease symptoms compared with the placebo group, and 65%met strict criteria for clinical remission (versus 35% of the placebo recipients). The cannabis group also had significant improvements in their quality of life compared with the placebo group. “We have previously demonstrated that cannabis can produce measurable improvements in Crohn’s disease symptoms4 but, to our surprise, we saw no statistically significant improvements in endoscopic scores or in the inflammatory markers we measured in the cannabis oil group compared with the placebo group,” said Dr Naftali. “We know that cannabinoids can have profound anti-inflammatory effects but this study indicates that the improvement in symptoms may not be related to these anti-inflammatory properties.” Looking ahead, the research group plans to explore further the potential anti-inflammatory properties of cannabis in the treatment of inflammatory bowel disease. “There are very good grounds to believe that the endocannabinoid system is a potential therapeutic target in Crohn’s disease and other gastrointestinal diseases,” said Dr Naftali. “For now, however, we can only consider medicinal cannabis as an alternative or additional intervention that provides temporary symptom relief for some people with Crohn’s disease.’ Notes to Editors For further information, or to arrange an interview with Dr Tinma Naftali, please contact Luke Paskins on +44 (0)1444 811099 or media@ueg.eu About Dr Timna Naftali Dr Timna Naftali is an MD Specialist in Gastroenterology at Meir Hospital and Kupat Holim Clinic, Tel Aviv University, Israel. About UEG Week UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning. About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European medical specialist and national societies focusing on digestive health. Together, its member societies represent over 30,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. To advance the standards of gastroenterological care and knowledge across the world and to reduce the burden of digestive diseases, UEG offers numerous activities and initiatives, including:
  • UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
  • Activity Grants, promoting and funding educational projects in the field of digestive health to advance and harmonise the training and continuing education of professionals
  • UEG Journal, covering translational and clinical studies from all areas of gastroenterology
  • Public Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
  • Quality of Care, European-based and English clinical practice guidelines, clinical standards, consensus, position papers and standard protocols in the field of digestive health, are available in the repository
Luke Paskins on +44 (0)1444 811099 or media@ueg.eu Find out more about UEG’s work by visiting www.ueg.eu or contact:         Follow UEG on Twitter References
  1. Naftali T, Bar-Lev Schlieder L, Konikoff F, et al. Cannabis induces clinical response but no endoscopic response in Crohn’s disease patients. Presented at UEG Week Vienna 2018, October 22, 2018. 
  2. Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23(10):891-6.
  3. Weiss A, Friedenberg F. Patterns of cannabis use in patients with Inflammatory Bowel Disease: A population based analysis. Drug Alcohol Depend. 2015;156:84-89.
  4. Naftali T, Bar-Lev Schleider L, Dotan I, et al. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11(10):1276-1280.e1.

UEG Week: New research links Crohn’s disease to Black Death

UEG Week: New research links Crohn’s disease to Black Death

(Vienna, October 22, 2018) European incidence of Crohn’s disease is likely to be a result of surviving the Black Death in the middle ages, according to new research presented today at the 26th UEG Week in Vienna. 

Researchers from Paris, France studied historical data on the intensity of plague outbreaks from Europe and the Mediterranean Basin between 800 and 1850AD. They found that there was statistical significance between outbreak intensities and Crohn’s disease-associated mutations in the general population – which help to explain modern-day prevalence of Crohn’s disease in Europe. Crohn’s disease is a chronic relapsing condition that, together with ulcerative colitis, comprises the disease known as inflammatory bowel disease (IBD). The researchers looked at the gene NOD2 which plays an important role in the body’s immune system but mutations of which are related to the development of Crohn’s disease. Mutations of NOD2 have been shown to aid the resistance of the organism that causes the plague and the results of the study show that the prevalence of these mutations associated with Crohn’s disease are correlated with the intensities of plague outbreaks. Approximately 3 million Europeans are now affected by IBD, which costs European health systems up to €5.6 billion per year. The causes of IBD are not fully known, although research strongly suggests that both genetic and environmental factors play a significant role. IBD can lead to an increased risk of developing colorectal cancer and, whilst symptoms may develop at any age, the peak age of IBD onset is during adolescence or early adulthood. The Black Death was responsible for the deaths of millions of Europeans and is thought to have killed between 30-40% of the European population between 1347 and 1353. Professor Jean-Pierre Hugot, one of the leading researchers involved in the French study explains, “Considering the potential severity of Crohn’s disease when untreated, it is unlikely that it was a frequent disease before the 20th century. As healthcare systems have developed and care for Crohn’s disease patients has improved, more and more people are living with the disease. This research goes some way to explaining the genetic origins of Crohn’s and we hope it will enable us to better understand the disease, and how to treat it, in the future.” Notes to Editors For further information, or to arrange an interview with Professor Jean-Pierre Hugot, please contact Luke Paskins on +44 (0)1444 811099 or media@ueg.eu About Professor Jean-Pierre Hugot Professor Jean-Pierre Hugot is an IBD specialist and his research is focused on genetics and IBD. He is head of the Paediatric Digestive and Respiratory Diseases Department at the Robert Debré Hospital, Paris, France. About UEG Week UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning. About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European medical specialist and national societies focusing on digestive health. Together, its member societies represent over 30,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. To advance the standards of gastroenterological care and knowledge across the world and to reduce the burden of digestive diseases, UEG offers numerous activities and initiatives, including:
  • UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
  • Activity Grants, promoting and funding educational projects in the field of digestive health to advance and harmonise the training and continuing education of professionals
  • UEG Journal, covering translational and clinical studies from all areas of gastroenterology
  • Public Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
  • Quality of Care, European-based and English clinical practice guidelines, clinical standards, consensus, position papers and standard protocols in the field of digestive health, are available in the repository
Luke Paskins on +44 (0)1444 811099 or media@ueg.eu Find out more about UEG’s work by visiting www.ueg.eu or contact:         Follow UEG on Twitter  References
  1. Dumay, A. et al (2018), Is Crohn’s Disease the price to pay today for having survived the Black Death? Presented at UEG Week Vienna 2018, October 22, 2018.
  2. Yamamoto, S & Ma, X (2009), Role of Nod2 in the development of Crohn’s disease. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924159/  
  3. Burisch, J. et al (2013), The burden of inflammatory bowel disease in Europe. Available at: https://www.sciencedirect.com/science/article/pii/S1873994613000305
  4. United European Gastroenterology (2012), The Survey of Digestive Health in Europe. Available at: https://www.ueg.eu/research/white-book/

Europe is “failing” to deal with chronic digestive disease burden

Europe is "failing" to deal with chronic digestive disease burden

(Brussels, May 15, 2018) Europe is currently failing to manage the increasing burden inflicted by chronic digestive diseases, according to leading digestive health experts.

A report, published today during the launch of MEP Digestive Health Group, reveals alarming issues, challenges and inequalities in a range of chronic digestive-related diseases, including digestive cancers, alcohol-related digestive diseases, paediatric digestive diseases and functional gastrointestinal (GI) disorders. Upon reviewing the latest statistics from across the continent and canvassing the opinions of both policymakers and scientific experts, the report reveals: 
  • 59% of men and 45% of women in the EU aged 18 and above are overweight
  • Digestive cancers represent 28% of all cancer-related deaths in the EU (365,000 deaths)
  • One in four deaths from gastrointestinal diseases are directly attributed to alcohol
  • Inflammatory bowel disease diagnosis can commonly take up to five years  
The five most common digestive cancers – colorectal, gastric, pancreatic, liver and oesophageal cancer – are responsible for over 590,000 cases each year in the EU. If current population trends continue, the number of deaths from these cancers across the EU per year will increase by over 40% by 2035. Approximately half of all cancers are preventable and their significant burden could be reduced by addressing lifestyle factors, such as rising levels of obesity and heavy alcohol consumption. Obesity, for example, is quickly overtaking tobacco as a health risk and is the leading preventable cause of cancer and substantially threatens the sustainability of public healthcare systems. In addition to the threat posed from digestive cancers and obesity, experts are also warning of the socioeconomic burden inflicted by functional GI disorders, such as irritable bowel syndrome (IBS) and constipation. Functional GI disorders are common conditions that can be extremely disabling for patients, yet sufferers often do not consult their physician about their symptoms. They are associated with educational and occupational absenteeism, imposing high costs to society, and are expensive to treat and manage. Treating IBS in Germany alone, for example, is estimated to cost over €3.2 billion per year. Professor Markus Peck, of United European Gastroenterology, which represents over 22,000 digestive health specialists, comments, “The impact inflicted by digestive diseases continues to increase across Europe. With chronic digestive diseases, our society fails and the burden is only going to become greater. We’re seeing notable increases in the incidence of most gastrointestinal disorders, from digestive cancers to liver disease. The current outlook for young people’s health, for example, is extremely alarming, with childhood obesity rates expected to almost double by 2025.” Current predictions, trends and attitudes demonstrate that the challenge presented by obesity, heavy alcohol consumption and poor nutritional choices is increasing and urgent action is required to reduce this burden and improve health outcomes in generations to come. To address this difficult challenge, policymakers and digestive health experts will meet today in the European Parliament to inaugurate the MEP Digestive Health Group. The group’s overarching mission is to ensure that continually improving digestive health becomes and remains an integral part of the EU health agenda, serving as a platform of exchange between the scientific community and policymakers. “Rising obesity levels, functional GI-disorders and heavy alcohol consumption across Europe have major implications for future healthcare provision and it is essential that these largely preventable issues are tackled through health policy and action” adds Professor Peck. “United European Gastroenterology welcome the MEP Digestive Health Group and look forward to close collaboration in achieving the mission of tackling the burden of chronic digestive diseases across Europe.” References:
  1. Digestive Health Across Europe: Issues, Challenges and Inequalities (2018). United European Gastroenterology and the MEP Digestive Health Group. 
Access the Digestive Health Across Europe Report Notes to Editors For further information, or to arrange an expert interview, please contact Luke Paskins on +44 (0)1444 811099 or media@ueg.eu About Professor Markus Peck Professor Markus Peck is Chair of the UEG Public Affairs Committee and former Secretary General of EASL (European Association of the Study of the Liver).  About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 25,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives, including:
  • UEG Week, the biggest congress of its kind in Europe, and one of the two largest in the world.
  • UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
  • Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
  • UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
  • EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
  • Quality of Care, European-based and English clinical practice guidelines, clinical standards, consensus, position papers and standard protocols in the field of digestive health, are available in the repository.
Find out more about UEG’s work by visiting www.ueg.eu or contact:            Luke Paskins on +44 (0)1444 811099 or media@ueg.eu

Child Safety Risk as Three Quarters of Paediatric IBD Patients Not Meeting Recommended Calcium and Vitamin D Intake

Child Safety Risk as Three Quarters of Paediatric IBD Patients Not Meeting Recommended Calcium and Vitamin D Intake

(Vienna, 15 May, 2017) A new study highlights that children suffering from inflammatory bowel disease (IBD) are not meeting the daily recommended intake of calcium and vitamin D. The research, conducted at Great Ormond Street Hospital for Children in London, identified that only 26.6% and 21.3% of paediatric IBD patients were achieving the current recommended intake for calcium and vitamin D respectively.

Medical experts from United European Gastroenterology (UEG) are therefore calling for immediate intervention to ensure that paediatric IBD patients are not put at risk of experiencing poor bone health and development, calcium homeostasis imbalance and vitamin D deficiencies. Achieving optimal levels of calcium and vitamin D is essential for developing children, especially in patients with IBD, as research suggests that children and adolescents with the disease develop suboptimal bone health in comparison to their peers. Therefore, they may not achieve optimal bone mineralisation, resulting in an increased risk of permanent height deficits. Vitamin D and calcium both play a major role in bone health and recently vitamin D has shown to potentiate the effect of anti-inflammatory treatments. However, ensuring a sufficient intake of vitamin D and calcium in children can be challenging. Rita Shergill-Bonner, Principle Dietician at Great Ormond Street Hospital for Children, London, explains, “When taking into account their young age and modern eating habits, coupled with the emotional, psychological and physical stress of living with IBD, it can be hard for paediatric patients to maintain a balanced diet and a sufficient intake of the right nutrients. We therefore urge the parents and carers of paediatric IBD patients to monitor their children’s diets carefully to ensure they are consuming the right foods to help their disease course and ensure adequate and normal development.”

“It is imperative that healthcare professionals provide all IBD patients with regular and frequent advice on nutrition and healthy eating habits, including guidance on food sources that are rich in calcium and vitamin D” - Professor Gigi Veereman, UEG paediatric IBD expert.

There is no solitary cause of IBD but it is thought to be due to a combination of genetic and environmental factors. Incidence rates have been steadily increasing over the past few decades and one in four cases of the disease are diagnosed during childhood. Physical IBD symptoms can be extremely debilitating, including severe abdominal pain, diarrhoea, weight loss and fatigue. The disease can also have a significant impact on a patient’s psychological, emotional and mental health, with over half of sufferers feeling that the disease negatively affects their education. Professor Philippe van Hootegem, UEG IBD expert comments, “There are many effective drugs available to help treat IBD but there are still a lot of unmet needs in both child and adult patients. Interesting and hopeful new drugs, some of which are to be taken orally, are in their final development stage. Nevertheless, a definitive curative therapy is not on the horizon yet and future research is still needed.” “It is imperative that healthcare professionals provide all IBD patients with regular and frequent advice on nutrition and healthy eating habits, including guidance on food sources that are rich in calcium and vitamin D”, adds Professor Gigi Veereman, UEG paediatric IBD expert. “Tailored care services, long-term follow up, regular reviews and frequent medical interventions are required to minimise additional health risk in our paediatric patients” May 29 is World Digestive Health Day and this year health organisations from around the world are coming together to highlight the issues affecting patients living with IBD.

Notes to Editors For further information and to schedule an interview with Professor Philippe van Hootegem, Professor Gigi Veereman or Rita Shergill-Bonner, please email media@ueg.eu or phone Luke Paskins on +44 (0)1444 811099 The IBD Journey Video View the IBD Journey animated video Inflammatory Bowel Disease Infographic View and download our infographic on paediatric inflammatory bowel disease About Professor Philippe van Hootegem Professor Philippe van Hootegem is a member of the UEG Public Affairs Committee and a Consultant Gastroenterologist at the Sint-Lucas General Hospital, Bruges, Belgium. About Professor Gigi Veereman Professor Gigi Veereman is a member of the UEG Public Affairs Committee and a Paediatric Gastroenterologist at the University Hospital, Brussels, Belgium. About Rita Shergill-Bonner Rita Shergill-Bonner is a Principle Gastroenterology Dietician at Great Ormond Street Hospital for Children, London, England. About the Research The study was presented at the 12th Congress of ECCO, Barcelona, February 15-18, 2017. About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. Find out more by visiting www.ueg.eu To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives, including: 
  • UEG Week, the biggest congress of its kind in Europe, and one of the two largest in the world
  • UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
  • Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
  • UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
  • EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
References 
  1. Shergill-Bonner R., et al. Paediatric IBD patients do not meet the daily recommendations of vitamin D and calcium intake: survey based analysis in a tertiary centre. Presented at the 12th Congress of ECCO, Barcelona, February 15-18, 2017. Available here: https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2017/item/p707-paediatric-ibd-patients-do-not-meet-the-daily-recommendations-of-vitamin-d-and-calcium-intake-survey-based-analysis-in-a-tertiary-centre-2.html
  2. B. Wilson, S. Lönnfors, S. Vermeire. The true impact of IBD: a European Crohn’s and Ulcerative Colitis patient life. IMPACT Survey 2010-2011. Available here: http://www.efcca.org/sites/default/files/IMPACT-STUDIE_online.pdf

UEG Week: Experts call for urgent change in the care of young adults with IBD

UEG Week: Experts call for urgent change in the care of young adults with IBD

(Vienna, October 19, 2016) Today, world leading digestive health experts are presenting a pioneering new programme that could have a significant impact on the quality of life of young adults living with inflammatory bowel disease (IBD). Experts believe that the programme could help combat the poor and, in some cases, life-threatening care offered to young IBD patients across Europe.

IBD can be an extremely debilitating condition and one of the key issues concerning clinicians is the transition from paediatric to adult care. This is fraught with difficulty and, with the incidence of paediatric IBD currently rising, many young people enter adult care with extreme and complex forms of the disease which is often mismanaged. The lack of support and effective management during the transition can have severe consequences for both the individual and the healthcare system. 

The Berliner TransitionsProgramm (BTP), established in Germany, has reported its first successes in the safe and effective transition of childhood IBD patients into adult care. The programme lasts two years for each child and involves close collaboration between paediatricians and adult care colleagues.

Professor Britta Siegmund, a member of the BTP Task Force discussed the encouraging findings at UEG Week 2016. “Following the success of results in other disease areas, IBD was incorporated into the programme two years ago. Transitioning programmes are initiated in the paediatric setting and involve a gradual process aimed at building the young person’s understanding of their condition to help prepare them and their families for a move into adult care. So far, our experience demonstrates that the young people who have taken part have arrived into adult care very positively.” 

The BTP can serve as a role model that can be adapted to the health service of each country.

One in four cases of IBD are diagnosed during childhood and over 50% of sufferers believe that IBD negatively effects their education. “With the change of care occurring at such a crucial age for our patients, it highlights the importance of a smooth and supportive transition to enable young adults to lead normal lives and prevent the disease from impacting their education and lifestyle” says Professor Siegmund. 

As well as IBD, the BTP also includes other long-term paediatric conditions, such as juvenile diabetes, epilepsy, arthritis, kidney disease and asthma. When a patient is included in the programme, a case manager is assigned who takes care of all the practical issues, maintains contact with the patient throughout the process and ensures that they are comfortable throughout the programme. Where needed, the patient can see both their paediatrician and their new treatment team during the transition.  

Providing all the materials, structure and support required to transition children safely, Professor Siegmund hopes that the success of the programme will provide a framework that can be incorporated across the rest of Europe. She explains, “The BTP can serve as a role model that can be adapted to the health service of each country. One of the critical success factors for the programme is to ensure that children are transitioned into the care of specialists who really understand adolescents and are willing to invest the time in them. All physicians who agree to take part in the programme fulfil this requirement and are committed to the success of the project.”

For more information on the BTP, please visit: http://www.drk-kliniken-berlin.de/westend/krankenhaus-westend/berliner-transitionsprogramm/

Access the release in German (PDF)
Access the release in English (PDF)

References 

1.    UEG  EU Affairs. Paediatric Digestive Health Across Europe: Early Nutrition, Liver Disease and Inflammatory Bowel Disease. Available at: https://www.ueg.eu/epaper/UEG_Paediatric_Digestive_Health_Report/index.html

2.    Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am 1999;28:445–58.

3.    Trivedi I, Holl JL, Hanauer S et al. Integrating adolescents and young adults into adult-centered care for IBD. Curr Gastroenterol Rep 2016;18:21.

4.    The IMPACT Survey, 2011, EFCCA. Available at: http://efcca-solutions.net/

Notes to Editors 

For further information, or to arrange an interview with Professor Britta Siegmund, please contact Luke Paskins on +44 (0)1444 811099 or media@ueg.eu

About Professor Britta Siegmund

Professor Siegmund is from the Medical University of Berlin and is a member of the Berliner TransitionsProgramm in inflammatory bowel disease. Her interests include contributing towards the understanding of inflammatory bowel disease and identifying possible novel therapeutic targets.

About Professor Gigi Veereman (UEG Spokesperson)

Professor Veereman is a member of the UEG Public Affairs Committee and Secretary General at the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. 

About UEG Week

UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress, attracting up to 13,000 participants from 116 countries. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning.

About UEG

UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.

To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives, including: 

  • UEG Week, the biggest congress of its kind in Europe, and one of the two largest in the world.
  • UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
  • Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
  • UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
  • EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe

Find out more about UEG’s work by visiting www.ueg.eu or contact:           

Luke Paskins on +44 (0)1444 811099 or media@ueg.eu

Follow UEG on Twitter

UEG Week: Clinicians welcome new initiatives to help improve outcomes for patients with functional GI disorders

UEG Week: Clinicians welcome new initiatives to help improve outcomes for patients with functional GI disorders

(Vienna, October 18, 2016) European clinicians and research scientists attending UEG Week 2016 have welcomed the publication of new criteria for the diagnosis and classification of functional gastrointestinal (GI) disorders, together with the launch of several major initiatives designed to enhance understanding of these disorders and help clinicians in the care of their patients. Delegates attending UEG Week in Vienna embraced the initiatives, which have been inspired by publication of the new Rome IV criteria for functional GI disorders and were showcased today by Dr Douglas A. Drossman, the current President of the Rome Foundation.  

Speaking at UEG Week, Dr Drossman outlined the need to update the definitions and conceptual understanding of functional GI disorders, leading to the development of the Rome IV classification and the research and educational initiatives that have followed. “The Rome III criteria were published in 2006 and, in the last 10 years, we have seen unprecedented progress in our understanding of functional GI disorders and now have better treatments available for many of them,” he said. “In developing the Rome IV criteria, we wanted to include new diagnoses, emphasize the importance of the gut­–brain interaction in the pathophysiology of these conditions, and improve their diagnosis and treatment using new learning tools.”

We now want to help clinicians in Europe and around the world to understand the new criteria, integrate them into their own diagnostic work-ups and optimize their patient management.

What’s new in Rome IV?

The Rome IV criteria contain a number of major changes, which were based on both new evidence and expert consensus. Major changes in Rome IV include: 

  • The redefinition of functional GI disorders as ‘disorders of the gut–brain interaction’ and the removal of the term, ‘functional’ when not needed.
  • The addition of new diagnoses, including opioid-induced constipation, narcotic bowel syndrome, cannabinoid hyperemesis syndrome and reflux hypersensitivity.
  • Threshold changes for diagnostic criteria to improve their clinical meaningfulness.
  • Revision of sphincter of Oddi (SOD) disorder criteria
  • Reconceptualization of irritable bowel syndrome (IBS) and its sub-types, with removal of the term ‘discomfort’ from its diagnostic criteria. 

“These changes reflect our growing understanding of many different aspects of functional GI disorders and they should help support future research and enhance clinical practice,” said Dr Drossman. “We now want to help clinicians in Europe and around the world to understand the new criteria, integrate them into their own diagnostic work-ups and optimize their patient management.” 

To aid in the communication of the Rome IV concepts to clinicians, the educational materials have been published as the Rome IV 2-volume textbook and also supplementary clinically oriented books. These include diagnostic algorithms, multimodal treatment using the Multi-Dimensional Clinical Profile, as well as paediatric and primary care books. “In this manner, the clinician can find the book that is best targeted to his or specific interests” said Dr Drossman. 

Rome IV Interactive Clinical Decision Toolkit

As a means to further reach the needs of clinicians, the Rome Foundation has been working with new software to develop a powerful on-line, interactive toolkit that presents a combination of Rome IV diagnostic algorithms and Multidimensional Clinical Profile (MDCP) treatment guidelines. The toolkit guides clinicians through the complex challenges of working with patients with functional GI disorders, with users seeing all relevant decision pathways, and, by inputting their patients’ information, activating the pathways that lead to treatment recommendations for optimal outcomes. 

“Both the Rome IV diagnostic criteria and the MDCP guidelines are innovative in their learning approaches and we are pleased to have been able to combine these approaches in this interactive on-line toolkit,” explained Dr Drossman. “We anticipate that clinicians will be able to develop a more comprehensive knowledge and optimize the care of their patients by accessing the most up-to-date information developed by world experts.” 

Access the release in German (PDF)
Access the release in English (PDF)

References

1.    Drossman DA, Chang L, Chey WD, Kellow J, Tack J, Whitehead WE (eds). Rome IV functional gastrointestinal disorders: disorders of gut–brain interaction. Raleigh, NC: Rome Foundation, 2016.

2.    Drossman DA, Chang L, Chey WD, Kellow J, Tack J, Whitehead WE and the Rome IV Committees (eds). Rome IV Multidimensional Clinical Profile for Functional Gastrointestinal Disorders (2nd edition). Raleigh, NC: Rome Foundation, 2016. 

Notes to Editors

For further information, or to arrange an interview with Dr Douglas Drossman, please contact Luke Paskins on +44 (0)1444 811099 or media@ueg.eu

About Dr Douglas Drossman

Dr Drossman is the current President of the Rome Foundation and his research relates to the clinical, epidemiological, psychosocial and treatment aspect of functional GI disorders. He has served as the Associated Editor of the journal Gastroenterology and has written over 500 articles and book chapters. 

About Professor Magnus Simren (UEG Spokesperson)

Professor Magnus Simren is the Chair of the UEG Scientific Committee and is a Consultant in the Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden. Professor Simren also sits on the Rome IV Committee, within the Microbiota Working Team.

About UEG Week

UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress, attracting up to 13,000 participants from 116 countries. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning.

About UEG

UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.

To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives, including: 

  • UEG Week, the biggest congress of its kind in Europe, and one of the two largest in the world.
  • UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
  • Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
  • UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
  • EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe

Find out more about UEG’s work by visiting www.ueg.eu or contact:           

Luke Paskins on +44 (0)1444 811099 or media@ueg.eu

Follow UEG on Twitter

New research shows impact of Crohn’s disease on brain function

New research shows impact of Crohn’s disease on brain function

(Vienna, 24 August 2016) New research published in the UEG Journal has found that Crohn’s disease sufferers experience slower response times than matched individuals that do not have the disease.

In a study of patients with Crohn’s disease, cognitive response times were 10% slower than normal and significantly correlated with symptoms of active inflammation, including abdominal pain and fatigue. Notably, the response times in Crohn’s patients were slower than those assessed in people over the legal drink drive limit in most EU countries (blood alcohol content above 0.05 g/100ml) when assessed with the same computer-based cognitive test in a similar study by the same group.  The results demonstrate the presence of mild cognitive impairment in Crohn’s patients and support patients’ frequent complaints of difficulties in concentration, clouding of thought and memory lapses. The study also demonstrated that Crohn’s patients had a higher median depression score and a poorer rating of sleep quality, which were associated with more severe cognitive impairment.  Crohn’s disease, one of the two main forms of inflammatory bowel disease (IBD) alongside ulcerative colitis, has seen a sharp increase throughout much of Europe in recent decades with higher incidence levels documented in northern and western parts of the continent. The disease can be extremely debilitating for patients and there is no solitary cause, although it is thought to be due to a combination of genetic and environmental factors.

The research highlights the need for regular interventions with multi-disciplinary IBD teams to address the wide issues that are presented with Crohn's disease.

As well as the recognised bowel-related symptoms of Crohn’s disease such as abdominal pain and diarrhoea, the condition has now also been shown to impact cognitive function. Patients frequently experience cognitive symptoms, yet these symptoms are often ignored by clinicians. Dr Daniel van Langenberg, the lead researcher behind the findings, comments, “These results reinforce the notion that Crohn’s has a wide range of multi-systemic consequences with the impact of the disease affecting patients not only within but well beyond the digestive tract.”
Dr van Langenberg adds, “The findings appear consistent with experiments that have shown that bowel inflammation results in an upregulation of inflammatory hippocampus activity in the brain. This, in turn, might account for the slower response times that were observed in the study.” Professor Gigi Veereman, UEG inflammatory bowel disease expert, comments “This research highlights the need for regular interventions with multi-disciplinary IBD teams to address the wide issues that are presented with Crohn’s disease. This will enable a greater understanding of this complex condition and therefore improve the service and care offered to each patient.” Access the research in the UEG Journal Notes to Editors About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. Find out more by visiting www.ueg.eu To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives, including: 
  • UEG Week, the biggest congress of its kind in Europe, and one of the two largest in the world
  • UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
  • Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
  • UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
  • EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
About Dr van Langenberg Dr Daniel van Langenberg is the Head of IBD Service, Eastern Health and a Senior Lecturer at Monash University in Victoria, Australia. He is involved with clinical and research activities with specific interest and expertise in inflammatory bowel disease and function gastrointestinal disorders. About Professor Gigi Veereman Professor Gigi Veereman is a member of the UEG Public Affairs Committee and Secretary General of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN).   References  
  1. van Langenberg DR, Yelland GW, Robinson SR, Gibson PR. Cognitive impairment in Crohn’s disease is associated with systemic inflammation, symptom burden and sleep disturbance. UEG Journal. August 2016: http://ueg.sagepub.com/content/early/2016/08/07/2050640616663397.full.pdf+html
  2. Roberts SE, Samuel DG, Williams JG, et al. Survey of Digestive Health across Europe. Part one: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe. Report for United European Gastroenterology. October 2014: http://ueg.sagepub.com/content/suppl/2014/10/13/2050640614554154.DC1/Full_Survey.pdf

IBD drug availability putting children at risk of lifelong health complications

IBD drug availability putting children at risk of lifelong health complications

(Vienna, June 21, 2016) At least a quarter of all patients with inflammatory bowel disease (IBD) present symptoms during childhood. However, delays in paediatric clinical trials result in off-label adult medications being prescribed for children, with serious lifelong health risks, including growth failure and cancer. 

To halt the health risks for children and improve outcomes in the future, IBD experts across Europe are calling for an urgent increase in investment into paediatric clinical trials to ensure more drugs become available to improve treatment efficacy and reduce serious and unnecessary risks of therapy. Professor Gigi Veereman, spokesperson for United European Gastroenterology (UEG) and Consultant in Paediatric Gastroenterology and Nutrition, is leading the call for change and explains; “In spite of recent investment to advance the care of patients with paediatric inflammatory bowel disease all over Europe, there is still an urgent need for more paediatric clinical trials. We need to speed up the availability of appropriately formulated licensed treatments with proven safety profiles so that children with IBD can attain their full psycho-social and physical potential into adulthood, without any unnecessary long-term health risks such as growth failure, severe  infections and cancer. In addition, research on the effect of nutrition and the environment on these chronic diseases is very much needed.” According to UEG’s Survey of Digestive Health across Europe, the incidence of IBD has been steadily increasing across Europe over the last few decades and as many as 30% of all cases are diagnosed during childhood. However, traditional adult based therapies currently prescribed for children with inflammatory bowel disease can have potentially negative effects on the developing body, an example being the effects of corticosteroid therapy on bone density.  In fact, prolonged corticosteroid use has been found to contribute to the significant reduction in final adult height of almost 1 in 5 children.  Furthermore, recent studies report that younger patients also have treatment related complications, including the development of malignancies.  Specifically, some immunosuppressants have been found to increase the risk of skin cancers and uterine cervical cancers.  Currently, most of the drugs that are used in paediatric IBD have only been tested in children in small uncontrolled trials and only a few of the drugs have been approved for use in children after proper multicenter trials, resulting in a substantial proportion being prescribed off-label. As Professor Veereman highlights; “Children with IBD have different specific treatment needs and medication should aim beyond symptom control and also include restoration of growth and prevention of pubertal delay.” Luisa Avedano, CEO of the European Federation of Crohn’s and Ulcerative Colitis Association (EFCCA) adds; “IBD is becoming more and more common in children and can have a more severe disease course and worse prognosis than when diagnosed in adulthood. Children with inflammatory bowel disease often present around the time of their pubertal growth spurt, a time of dramatic psychological and physical transition for a child, so specific attention with medication should be paid to preventing disturbances in growth and development.” Significant improvements in the availability of specific paediatric IBD drugs is just one of a number of issues being raised by UEG as part of its initiative to improve the state of paediatric digestive health for the next generation throughout Europe. Notes to Editors For further information or to speak with Professor Gigi Veereman (or local paediatric digestive health expert) please contact Luke Paskins at UEG on +44 (0)1444 811099 or email media@ueg.eu Paediatric Digestive Health Across Europe – a report by UEG on the current state of early nutrition, liver disease and inflammatory bowel disease across Europe is available here.  About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. Find out more by visiting www.ueg.eu To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives, including:
  • UEG Week, the biggest congress of its kind in Europe, and one of the two largest in the world. NOW OPEN FOR PRESS REGISTRATION
  • UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
  • Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
  • UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
  • EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe

References
  1. United European Gastroenterology Journal: (1) Farthing M, Roberts S, Samuel D, Williams D, et al, Survey of digestive health across Europe: Final report. Part 1: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe, 2014 2: 195-196
  2. United European Gastroenterology Journal: (1) Farthing M, Roberts S, Samuel D, Williams D, et al, Survey of digestive health across Europe: Final report. Part 1: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe, 2014 2: 195-196
  3. Heuschkel R, Salvestrini C, Beattie RM et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2008 Jun; 14 (6): 839-49
  4. Jauregui-Amezaga A, Vermeire S, Prenen H ‘Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer.’ Ann Gastroenterol. 2016 Apr-Jun; 29 (2): 127-36
  5. Malmborg P, Hildebrand P ‘The emerging global epidemic of paediatric inflammatory disease – causes and consequences.’ Journal of Internal Medicine 2016 March; 279 (3): 241-258
  6. United European Gastroenterology. Paediatric Digestive Health Across Europe. May 2016

Children’s digestive health across Europe in crisis

Children’s digestive health across Europe in crisis

(Brussels, 31 May, 2016) A report investigating the current state of digestive health in children has revealed alarming trends in disease incidence and inequalities in the provision of digestive healthcare services for children across Europe. 

‘Paediatric Digestive Health Across Europe’, commissioned by United European Gastroenterology (UEG), is published today and highlights how the current health burden and economic pressure of paediatric digestive health issues, in particular the increasing levels of childhood obesity, have become a pandemic issue throughout the continent.  The report canvasses the opinion of a number of paediatric GI specialists, including experts from UEG and current and past presidents of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), who highlight three particular areas of digestive health that show worrying trends and require urgent action. These include:  
  • In 46 European countries, one in every three children aged 6-9 years is now overweight or obese
  • Childhood onset of inflammatory bowel disease now accounts for 20-30% of all IBD cases
  • Non-alcoholic fatty liver disease has become the most common cause of chronic liver disease among children and adolescents in Western countries, with cases documented in children as young as 3 years old
Commenting on the current state of paediatric digestive health care in Europe, Professor Michael Manns, President of UEG, explains; “Across Europe we have leading paediatric experts and many centres of excellence. However, these are not widespread and currently cannot meet the needs of children throughout the continent. This has an impact on not just individuals and their families but on society and wider health service provision”. A call for change across Europe One of the main findings in the report is that many areas of digestive health follow a ‘one size fits all’ approach with many children following adult care pathways. Professor Berthold Koletzko, President of ESPGHAN, comments; “It is important for stakeholders and policy makers to appreciate that children have complex physical, psychological and social needs and these must be met by trained paediatric specialists to improve the accessibility of optimal care for children today and in future generations”. The report calls for urgent attention and resource investment in paediatric digestive health treatments and services to improve the prognosis for children who suffer from varying digestive health conditions.  A 6 point action plan, targeting key policy makers, stakeholders and health service providers, is outlined within the report to help encourage and deliver change and improve paediatric care across Europe. The 6 key actions are:  
  1. Further development of national strategies and public health campaigns for education, prevention and early intervention
  2. Improve and harmonise training standards through the development of a pan-European digestive health syllabus
  3. Enhance paediatric subspecialty training to understand the complex physical, psychological and social needs of children
  4. Develop transition services as patients move from teenage to adult care
  5. Encourage further research into childhood digestive diseases and early life programming to enable improved prevention strategies
  6. Further development of specialised centres for the optimal management of children with digestive diseases
The report will be issued to European policy makers today at the European Parliament, who will meet with leading health experts to discuss the latest research and areas for development examined in the review. The report is unveiled as part of UEG’s Digestive Health Month to raise awareness of digestive health issues across the continent. “In spite of 20% of the European population being children and the incidence of gastrointestinal diseases increasing, it is extremely worrying that only 1 out of 58 topics currently receiving EU research funding is focused on paediatric health” explains Professor Koletzko. “Priorities need to change quickly to appreciate the specific issues of paediatric digestive provision and ensure greater investment into prevention, cost-effective diagnostic measures and harmonised training”. Professor Manns adds; “UEG hope this report will encourage policy makers, stakeholders and health service providers to adopt the recommendations and prioritise the development of specific paediatric focused strategies for improving the digestive health of children today and for future generations”.

Access the report

Notes to Editors About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. Find out more by visiting www.ueg.eu To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives, including: 
  • UEG Week, the biggest congress of its kind in Europe, and one of the two largest in the world. 
  • NOW OPEN FOR PRESS REGISTRATION
  • UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
  • Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
  • UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
  • EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
About the Report Commissioned by UEG, Paediatric Digestive Health Across Europe, is a report that highlights the current levels of quality in paediatric digestive health throughout Europe, the current state of service provision and the potential impact on longer-term health outcomes and economies. The opinions of leading gastroenterologists and patient organisations have been utilised to help identify priority areas for improvement both now and in the future. Other key trends raised in the report include: 
  • It is predicted that the global number of children under five who are overweight will rise from the current 41 million to 70 million by 2025
  • The high cost of treating obesity and related disorders now represents up to 10% of total healthcare costs and threatens the sustainability of public healthcare systems across Europe
  • Delays in diagnosis of inflammatory bowel disease are taking up to 5 years for 18% of under 18’s
  • Non-alcoholic fatty liver disease prevalence continues to rise among paediatric patients, affecting up to 10% of Europe’s paediatric population
UEG Digestive Health Month The first UEG Digestive Health month, organised by United European Gastroenterology (UEG), has taken place throughout May. Held to raise awareness of digestive health conditions in Europe and highlight opportunities to help advance the treatment and prevention of related diseases, activity has featured on social media via the hashtag #DigestiveHealthMonth Contact Information For further information about the report and UEG’s activities, or to speak to a paediatric digestive health expert please contact Luke Paskins at UEG on +44 (0)1444 811099 or email media@ueg.eu References 
  1. http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/policy
  2. United European Gastroenterology Journal: (1) Farthing M, Roberts S, Samuel D, Williams D, et al, Survey of digestive health across Europe: Final report. Part 1: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe, 2014 2: 539-543
  3. Day CP. Non-alcoholic fatty liver disease: a massive problem. Clin Med. 2011; 11:176-178
  4. 1000 Days: http://thousanddays.org/the-issue/obesity/
  5. Early Nutrition Project: http://www.kcl.ac.uk/lsm/research/divisions/wh/newsevents/newsarchive/earlynutritionfactsheet.pdf
  6. B. Wilson, S. Lönnfors, S. Vermeire. The true impact of IBD: a European Crohn's and Ulcerative Colitis patient life. IMPACT Survey 2010-2011 http://efcca.org/media/files/press-Join-Fight/3PRESS_KIT_IBD_IMPACT_REPORT_BCN.pdf
  7. http://www.childliverdisease.org/News/Research-funded-by-Birmingham-charity-identifies-genetic-variant-in-childhood-liver-disease-

Vitamin D shows promise for treating Crohn’s disease in pilot study

Vitamin D shows promise for treating Crohn’s disease in pilot study

(June 10, 2015) New research published in this month’s edition of United European Gastroenterology Journal suggests that supplementation with vitamin D may  impact on the intestinal barrier dysfunction associated with Crohn’s disease, and could have a role in the treatment of the condition.

The study is by Professor Maria O’Sullivan and Tara Raftery. Department of Clinical Medicine, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin, Ireland. Crohn’s disease (CD) is a lifelong chronic relapsing and remitting gastrointestinal condition, characterised by inflammation, which can involve any portion of the gastrointestinal tract. CD is associated with abdominal pain, diarrhoea, fatigue and in many cases can result in a reduction of quality of life, time off work, hospitalisations and surgery. The exact causes are unknown; however, immune, genetic and environmental factors are thought to be involved. Incidence of CD varies across Europe, with up to 10 cases per 100,000 population per year. Generally, case rates are higher in northern and western Europe than southern and eastern Europe. There is emerging data that Vitamin D supplementation may prolong remission in CD; however, the clinical efficacy and underlying mechanisms remain unclear. In this new research, the authors aimed to determine changes in gut barrier function (as determined by intestinal permeability and antimicrobial peptide concentrations) as well as disease markers in CD, in response to vitamin D supplementation. In a double-blind randomised placebo-controlled study, the authors assigned 27 CD patients in remission to 2000 IU/day vitamin D supplementation or placebo for 3 months. They found, that patients treated with the supplementation were more likely to maintain their intestinal permeability, whereas this deteriorated in the placebo group. Increased intestinal permeability is considered a measure of gut leakiness, which is shown to predict and precede clinical relapse in CD. In addition, patients with the highest blood levels of vitamin D had signs of reduced inflammation (measured by C-reactive protein and antimicrobial peptides), and these patients also reported better quality of life. The authors conclude: “This is the first reporting of effects of vitamin D supplementation on intestinal permeability and antimicrobial peptide measures in a CD cohort. Whilst the data requires further confirmation, it broadly supports evidence from previous experimental studies that suggest a role for vitamin D in maintaining intestinal barrier integrity.”  Whilst the data is promising, the authors highlight that in order to understand its translation into treatment for CD, further larger randomised controlled trials will be required. UEG’s inflammatory bowel disease expert, Dr Charles Murray of the Royal Free Hospital, London, UK comments; “This is an exciting development in the treatment of Crohn’s disease and we welcome anything new that could potentially help patients with this debilitating condition”. Notes to Editors  Media Contacts Dr Charles Murray, Royal Free Hospital, London, UK - please contact Luke Paskins, UEG. T. +44 (0) 1444 811099.  E. media@ueg.eu Associate Professor Maria O’Sullivan, Department of Clinical Medicine, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin, Ireland. T. + 353 1 896 4039. E. maria.osullivan@tcd.ie About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives, including: · UEG Week, the biggest congress of its kind in Europe, and one of the two largest in the world. MEDIA REGISTRATION NOW OPEN · UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion · Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations · UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology · EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe Find out more about UEG’s work. Visit www.ueg.eu For further information and interviews, please contact:         Luke Paskins: media@ueg.eu Tel: +44 (0)1444 811099 References For the full UEG Journal article, see: http://ueg.sagepub.com/content/early/2015/02/06/2050640615572176.full.pdf+html For further information on incidence of Crohn’s disease in Europe, see: https://ueg.eu/epaper/WhiteBook.Brochure/index.html#/6

New study reveals 1 in 10 Inflammatory Bowel Disease patients are misdiagnosed with Irritable Bowel Syndrome

Study: 1 in 10 Inflammatory Bowel Disease patients are misdiagnosed with Irritable Bowel Syndrome.

(Vienna December, 15, 2014) A new study, published in the latest issue of the UEG Journal reveals that 10% of IBD patients are misdiagnosed with IBS and in 3% of cases the misdiagnosis can persist for five or more years. The case-controlled study, conducted in the UK, assessed the proportion of patients with IBS recorded prior to the IBD diagnosis to reveal the alarming statistics.

Leading IBD researcher and United European Gastroenterology (UEG) spokesperson Dr Michael Scharl says, “IBS has been estimated to affect at least 10% of the population in Europe and it causes distressing symptoms that disrupt normal life.” He explains, “We have known for some time that there are similarities between symptoms of IBS and IBD, but when it comes to diagnosis and treatment, this differs greatly.” He adds, “Misdiagnosis is understandable as many symptoms such as diarrhoea, abdominal cramping and pain are common to both and the specific alarm symptoms for IBD such as bloody stool, weight loss or fever are often absent in IBD patients in the initial phase of their disease. However, increased use of faecal calprotectin testing would help doctors distinguish between inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis and non-inflammatory bowel diseases, such as irritable bowel syndrome.” IBS has been estimated to affect at least 10 of the population in Europe. The initial misdiagnosis of IBD has serious consequences for patients, in particular those with Crohn's disease, since delays in diagnosis is correlated with an increased risk of bowel stenosis and CD-related intestinal surgery. Considering that the misdiagnosis of IBD might have severe consequences for a patient’s life, UEG are calling for increased efforts to be undertaken to screen symptomatic IBS patients for IBD. Screening tests for intestinal inflammation should be included in the work up of all new patients presenting with diarrhoea and pain. References: 1. Timothy R Card, Jesse Siffledeen and Kate M Fleming. Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database. 2: 505-512, UEG Journal December 2014. Available at: http://ueg.sagepub.com/content/2/6/505.full Notes to Editors About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. Find out more about UEG’s work. Visit www.ueg.eu Available for interview UEG Spokesperson, Dr Michael Scharl is an expert in both IBS and IBD and has recently been awarded a ‘UEG Rising Star’ award for his research which opens avenues for completely new treatment strategies for IBD and Crohn’s disease. Press contact Samantha Forster media@ueg.eu Tel: +44 (0)1444 811099 @UEGMedia

UEG puts the need for better care for IBD patients in Europe on the political agenda

UEG puts the need for better care for IBD patients in Europe on the political agenda.

(Vienna, December, 02, 2014) With inflammatory bowel disease (IBD) thought to cost the European Community over €2 billion in annual healthcare costs, United European Gastroenterology (UEG) is calling for EU politicians and leading decision-makers to take a more active role in reducing the burden of the disease.

Presenting the results of a major ‘Survey of Digestive Health Across Europe’, to  the European Parliament in Brussels today, UEG aim to draw attention to the impact IBD and other digestive and liver diseases have on the health and economy of the European community. The ‘Survey of Digestive Health across Europe’ highlights major differences in the incidence of gastrointestinal disorders and long-term health outcomes amongst European communities. Amongst IBD sufferers, incidence of Crohn’s disease was found to be highest in northern and western regions of Europe whilst ulcerative colitis had the highest incidence in Ireland, Denmark and Finland and the highest incidence of IBD overall is in France. According to UEG President, Professor Michael Farthing, “IBD has an increasingly crippling impact both to society and to individuals, particularly, the huge proportion of young people who suffer. UEG aim to raise awareness amongst the European Parliament of the debilitating symptoms and resulting impact on quality of life and performance.”  As many as 30% of all IBD patients presenting with symptoms are between the ages of 10 and 19 and nearly a fifth of under 18 year olds have to wait more than 5 years to receive a final diagnosis. Symptoms of IBD include faecal incontinence, abdominal cramping and extreme fatigue often resulting in depression and low self-esteem. The ‘Survey of Digestive Health Across Europe’ reveals that  21% of IBD sufferers across Europe felt they had been discriminated against in the workplace with 44% reported to have lost or had to leave their job. “The cost of IBD care has increased significantly over the past decade and it is vital that additional funding is made available to help reduce the health and societal burden of the disease through ensuring a quicker diagnosis and equitable access to the best treatment for all patients across Europe” adds Professor Farthing. Notes to Editors: About UEG United European Gastroenterology is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. Find out more about UEG’s work at www.ueg.eu UEG Events at European Parliament, Brussels – December 2nd, 2014 Digestive Health Survey and Healthcare in Europe 2040: Scenarios and Implications for Digestive and Liver Diseases presentations Host/Chairs: MEP Pavel Poc and Professor Michael Farthing (UEG President) “Inflammatory Bowel Disease: A  rising threat to the health of young Europeans” Debate Host/Chairs: MEPs Rebecca Harms/Michele Rivasi and Professor Theirry Ponchon (Chair, UEG Public Affairs Committee) Survey of Digestive Health Across Europe The Survey of Digestive Health Across Europe was commissioned by UEG in the spring of 2013 at the request of its own Future Trends Committee. An experienced research group from Swansea University in Wales, UK, initiated a detailed assessment of digestive health across Europe, focussing on the clinical and economic burden of disease and the organisation and delivery of gastroenterology services across 28 European Union (EU) member states, Norway, Switzerland, Liechtenstein and Russia. The aim of the survey was to draw together all the available evidence and provide up-to-date information on the human health consequences and public health burden of GI disorders. Available for interview Professor Michael Farthing, UEG President Press contact Samantha Forster media@ueg.eu Tel:+44(0)1444811099 @UEGMedia References 1. Roberts SE, Samuel DG, Williams JG, et al. Survey of Digestive Health across Europe. Part one: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe. Report for United European Gastroenterology. October 2014. 2. Anderson P, Dalziel K, Davies E et al. Survey of Digestive Health across Europe. Part two: The economic impact and burden of gastrointestinal diseases across Europe. Report for United European Gastroenterology. October 2014. 3. Problems in the diagnosis of IBD in children. H.A  Buller. Paediatric Gastroenterology and Nutrition, Academic Medical Centre, University of Amsterdam – The Netherlands Journal of Medicine. 4. EFCCA Impact of IBD Study 2010-2011. Published J Crohns and Colitis. 2014 March 21 5. The Inflammatory Bowel Disease in Young People - The impact on education and employment report - downloadable from the www.crohnsandcolitis.org.uk
<1 2>